{
  "abstract": "Tamoxifen is a non-steroidal selective oestrogen receptor modulator commonly used in the treatment of breast cancer. It is associated with the development of fatty liver and steatohepatitis however drug-induced liver injury is rare. We report a woman in her 50s who developed malaise with an acute moderate aminotransferase elevation without jaundice 6 months after starting tamoxifen. She was not commenced on any other recent drugs and extensive investigation including infective and autoimmune liver screen, cross-sectional imaging and FibroScan were unremarkable. Liver biopsy revealed moderate lobular hepatitis with hepatocyte drop-out. Tamoxifen was ceased and the liver enzymes showed resolution over the following 3 months and improvement of her symptoms.",
  "authors": [
    {
      "affiliations": [
        "Department of Hepatology, Sunshine Coast University Hospital, Birtinya, Queensland, Australia"
      ],
      "name": "Deloshaan Subhaharan"
    },
    {
      "affiliations": [
        "Department of Medical Oncology, Sunshine Coast University Hospital, Birtinya, Queensland, Australia"
      ],
      "name": "Grace Murphy"
    },
    {
      "affiliations": [
        "Department of Hepatology, Sunshine Coast University Hospital, Birtinya, Queensland, Australia"
      ],
      "name": "Natalie Commins"
    },
    {
      "affiliations": [
        "Department of Medical Oncology, Sunshine Coast University Hospital, Birtinya, Queensland, Australia"
      ],
      "name": "Mary Azer"
    }
  ],
  "title": "Drug-induced liver injury secondary to tamoxifen",
  "uid": "01f4e2ec-6f70-546b-8677-97466bf17995"
}